Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07625306 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL

StatusWithdrawn
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Withdrawn before enrolling Sponsor's reason: Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint Show 5 more changesShow less
    • Enrollment target: estimated 240 to confirmed 0
    • Primary and study completion pushed from Dec 7, 2028 to Jan 22, 2029
    • Start date changed from estimate of Aug 31, 2026 to Sep 1, 2026
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 2 of 9 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 34 trials at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Coronary Artery Disease
1,615 trials monitored
See 70 trials at risk
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS).
Trial Details
NCT Number NCT07625306
Lead Sponsor Novartis Pharmaceuticals
Conditions
(from sponsor)		 Acute Coronary Syndrome (ACS)
Related terms Acute Coronary Syndrome, Non-ST Elevated Myocardial Infarction, ST Elevation Myocardial Infarction
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov